A randomized phase 2 trial of paclitaxel, carboplatin and bevacizumab with or without PF-3512676 as first-line treatment of patients with advanced nonsquamous non-small cell lung cancer

Trial Profile

A randomized phase 2 trial of paclitaxel, carboplatin and bevacizumab with or without PF-3512676 as first-line treatment of patients with advanced nonsquamous non-small cell lung cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2008

At a glance

  • Drugs Agatolimod; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Aug 2008 Actual end date and patient numbers added as reported by ClinicalTrials.gov.
    • 21 Dec 2007 The expected completion date for this trial is 1 Jun 2009.
    • 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top